View a list of past awardees
ACTRI Pilot Projects
The call for applications for 2021 funding is now closed. If invited to do so, please note that Second Stage applications are now due by February 4, 2021 at 5pm.
UC San Diego Altman Clinical and Translational Research Institute (ACTRI) supports Pilot Projects that help fulfill the ACTRI mission of developing clinical and translational research. Pilot Project Grants are one-year competitive awards (up to $30,000) to provide funding for early stage projects. Pilot Projects are available to all CTRI members with faculty appointments; funding priority is given to early-career faculty.
Available Funding Categories:
- Clinical and Translational Research (up to $30,000)
Clinical Research is conducted with human subjects or on material collected from humans, in order to broaden knowledge about mechanisms of disease, therapeutic interventions, or clinical trials, or to develop new technology. Clinical research also includes epidemiological and observational studies, behavioral studies, community interventions, and research on outcomes and health services.
Translational Research projects are focused on applying basic research discoveries to the understanding of human disease pathogenesis or development of novel diagnostics or treatment modalities, including cell-based and other pre-clinical models.
Funds must be spent between May 1, 2021 and April 30, 2022. All funds not spent by the end date of the Pilot Project award will be returned to the ACTRI. No extensions can be granted. IRB approval must be obtained ASAP thereafter notice of intended award. No funds can be awarded until there is local IRB approval and secondary NCATS approval.
ACTRI Pilot Projects are also eligible for "in-kind"
vouchers. The vouchers can be used for ACTRI services only, including those related to the clinic, biostatistics, coordinators, and lab.
Applicants are permitted to request up to $5,000 in vouchers in addition to up to $30,000 for other aspects of their proposals.
We also encourage collaboration with other CTSA-funded institutions.
Applications are received in two stages. Stage 1 applications are now open.
- The first stage requires a 500-word abstract that will be scored.
- The second stage is by
invitation only based on review of the 500-word abstract. A five-page application is required, which will be scored according to modified NIH 9-point scoring guidelines that emphasize the future external funding potential of the investigator(s) and the project. Please submit your IRB application at the same time as submission of your second-stage application. We will require evidence that your application is slated for IRB review prior to ACTRI scientific review; if this is not available your application will be withdrawn for consideration during that cycle.
Application Deadline, Notices of Awards, and Funding Cycle
First Stage Application Deadline: Monday, November 9, 2020 @ 5 p.m. PT
Second Stage, by invitation only: Notification of invitation anticipated early December 2020
Second Stage Application Deadline: February 4, 2021 @ 5:00 p.m. PT
Notice of Awards: late February 2021
Funding Cycle: May 1, 2021 – April, 2022
Eligibility and Project Requirements
- Priority will be given to junior full-time faculty proposing collaborative projects.
Postdoctoral Fellows and Project Scientists are
- Principal Investigators for these pilot awards must be members of the ACTRI. Applicants may
join the ACTRI shortly before submission and still be eligible.
- Principal Investigators must be full-time faculty members at UC San Diego or one of the UC San Diego partner institutions including San Diego State University, Salk Institute, Sanford Burnham Prebys Medical Discovery Institute, J. Craig Venter Institute, La Jolla Institute for Allergy and Immunology, Rady Children's Hospital, and Palomar Pomerado Health.
- Previous awardees are not eligible to reapply for one year.
- Only one pilot proposal may be submitted by a Principal Investigator per funding category.
- Full professors are NOT eligible to be Principal Investigators unless they are entering a new line of research. Proposals cannot overlap with or be a logical extension of ongoing research. In general, proposals from full professors who have greater than $350,000/year in current funding will receive lower priority.
All investigators selected for funding will be required to submit a six-month progress report (including an in-person presentation) and a one-year Final Progress Report at the end of the funded project. An additional report one year later will also be required. This report will consist of a detailed description of progress to date and a listing of all submitted publications and grant applications (pending or funded), meeting abstracts and seminars relating to the pilot project.
Applications should be well-written, precise, and succinct. Applications will be subject to both scientific and programmatic review. The following criteria will be used in evaluating these proposals:
- Significance of the research and its translational relevance
- Scientific quality
- Feasibility to complete the project in one year
- Probability that the work will yield important new information, technology, or service and/or yield new federal funding
- Qualifications of the Principal Investigator and collaborators and inclusion of multidisciplinary team members
Presentations and Publications
Awardees are expected to publish their findings in scholarly peer-reviewed journals and present their research at professional meetings.
All publications, grants, and presentations resulting from research funded by the ACTRI or using ACTRI resources must cite the ACTRI as a contributing source of support and indicate the NIH CTSA grant title and number: University of California San Diego, NIH Grant
UL1TR001442. If a project is required to be registered at Clinicaltrials.gov, the Principal Investigator is responsible for doing so before beginning the research. ACTRI staff can help investigators with this process.
Investigators are responsible for submitting any peer-reviewed journal articles resulting from research funded by this award to PubMed Central, the NIH digital archive of biomedical and life sciences journal literature. See
How To Apply
How to Apply for Stage 1
- 500-word abstract
- NIH biographical sketches, including other support with yearly direct costs, for the significant participants
- The abstract page from all ongoing funded and pending research proposals
How to Apply for Stage 2
Stage 2 applications are
by invitation only based on scores received for Stage 1 applications.
- Five-page proposal description should follow NIH proposal criteria:
- Specific Aims
- Background and significance
- Preliminary studies (if applicable)
- Research design and methods
- Literature cited (not included in the five-page limit)
- A detailed budget with budget justification. All guidelines pertaining to allowable expenses on federal grants will be applicable for these awards. In addition,
no funding will be provided for travel, clerical help, office supplies, books and subscriptions, graduate student support and tuition remission, or publication expenses. If equipment is budgeted, it will need a thorough justification. As a reminder, these are pilot projects to obtain preliminary data.
- IRB applications must be submitted at the same time as the Stage 2 submission, and should provide evidence of IRB (HRPP) pending review (e.g., HRPP # for the project).
- Paragraph on community relevance (maximum 100 words) that includes the project title and is understandable at an eighth-grade reading level (non-scientist level reviewer). Paragraph should answer the following question, "How important is funding this research to improving human health, either in the near or distant future?" Do not include your name, as this paragraph will get a blinded review.
Applications should adhere to the following formatting specifications:
- 11‐point Arial font
- 0.5 inch margins on all sides
- 8 ½" x 11" (i.e. standard size) paper
- Number all pages
- No appendices are allowed
How to Submit your Application:
The application is available
You must register as an applicant. Do this at least a week prior to the submission deadline. You will be sent an email notifying you of your username and password after you register.
Don't wait to the last minute to submit as the system may be busy!!!
Murray Stein MD, MPH or call (858) 534-6451; or
Kathleen Kennedy or call (858) 822-0268 with any questions about this RFA or the application process.